Organon & Co Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $6.1B-4.3% YoYTTM through 30 Jun 2026
Net Income $209M-75.8% YoYTTM through 30 Jun 2026
Free Cash Flow $567MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 53.3% |
| EBITDA Margin | 13.6% |
| Operating Margin | 8.0% |
| Net Margin | 3.4% |
Returns
24.9%ROE
1.5%ROA
2.5%ROIC
Balance Sheet Health
Debt / Equity11.49x
Current Ratio1.82x
Net Debt$8.1B
Cash & Equivalents$1.1B
Quality Metrics
Altman Z-Score1.14
Piotroski F-Score4 / 9
FCF Margin9.3%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $6.2B
Diluted EPS$0.78TTMFY2025: $0.72
Dividend
$0.04Per share, FY20260.29%Yield-41.0%5-yr growth
Capital Allocation
Capex Intensity2.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Women's Health | $1.8B | -1.0% | View detailsWeighed down by U.S. policy restrictions on Nexplanon access since early 2025, offset by international growth and fertility expansion. |
| Biosimilars | $691M | +4.0% | View detailsFastest-growing segment, supported by new launches such as Bildyos and Bilprevda in late 2025. |
| Established Brands | $3.7B | -4.0% | View detailsFaces structural headwinds from loss of exclusivity (LOE) of Atozet in Europe and pricing pressures from China's VBP program. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.